Omass Therapeutics Ltd. has entered into an exclusive collaboration and license agreement with Genentech Inc., a member of the Roche Group, for the rights to develop and commercialize Omass’ preclinical oral small-molecule program for inflammatory bowel disease.
Scientists at Emory University and Hadasit Medical Research Services and Development Ltd. have described nuclear receptor ROR-α agonists reported to be useful for the treatment of liver cancer, pancreatitis, diabetes, obesity, immunological disorders, neurological disorders, liver diseases and metabolic diseases, among others.
Beijing Sciwind Biotechnology Co. Ltd. and Sciwind Biosciences Co. Ltd. have divulged glucagon-like peptide 2 receptor (GLP-2R) agonists reported to be useful for the treatment of Crohn’s disease, irritable bowel syndrome, malnutrition, ulcerative colitis, obesity and graft-vs.-host disease.
Gilead Sciences Inc. recently discussed the discovery of emvistegrast (GS-1427), a potent, selective, once-daily oral α4β7 integrin inhibitor currently in phase II trials for the treatment of inflammatory bowel disease (IBD) (NCT06290934).
Pfizer Inc. provided details on the discovery and in vitro/in vivo characteristics of SIK inhibitor PF-07899895 for the treatment of inflammatory bowel disease (IBD). Pfizer’s program focused on pan-SIK inhibition to regulate cytokine production in immune cells based on the hypothesis that this approach could suppress pro-inflammatory cytokines/chemokines and promote an anti-inflammatory phenotype.
Arnatar Therapeutics Inc.’s ART-4, an upregulating antisense oligonucleotide (ASO) therapeutic candidate for the treatment of Alagille syndrome (ALGS), has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA. Approximately 95% of ALGS cases are caused by haploinsufficient mutations in the Jagged-1 (JAG1) gene, leading to insufficient JAG1 protein levels and impaired liver bile duct development.
Apex Biosciences Pte Ltd. has identified phosphodiesterase PDE4B inhibitors reported to be useful for the treatment of cancer, neurological disorders, inflammatory bowel disease, skin inflammation, lung inflammation, eye inflammation and inflammatory joint diseases.
Shattuck Labs Inc. has reported that its IND from the U.S. FDA for SL-325 for the treatment of inflammatory bowel disease is now in effect. The company expects to commence a phase I trial in healthy volunteers in the third quarter of this year.
Takeda Pharmaceutical Co. Ltd. has divulged polypeptides acting as gastric inhibitory polypeptide receptor (GIPR) agonists reported to be useful for the treatment of nausea and vomiting.
Equillium Inc. has entered into a definitive securities purchase agreement with health care investors that will provide up to $50 million in gross proceeds to Equillium. The private placement will enable the company to advance its selective aryl hydrocarbon receptor (AhR) modulator EQ-504 into the clinic.
RSS
